Dark Forest Capital Management LP Buys New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dark Forest Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,000 shares of the company's stock, valued at approximately $441,000.

Several other hedge funds have also made changes to their positions in the business. BlackBarn Capital Partners LP increased its holdings in Teva Pharmaceutical Industries by 107.1% during the 4th quarter. BlackBarn Capital Partners LP now owns 1,050,000 shares of the company's stock worth $23,142,000 after purchasing an additional 543,029 shares during the period. Diadema Partners LP purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $6,677,000. Hsbc Holdings PLC raised its holdings in Teva Pharmaceutical Industries by 5.7% in the fourth quarter. Hsbc Holdings PLC now owns 561,289 shares of the company's stock valued at $12,374,000 after acquiring an additional 30,155 shares in the last quarter. Stifel Financial Corp grew its holdings in Teva Pharmaceutical Industries by 33.3% during the 4th quarter. Stifel Financial Corp now owns 88,478 shares of the company's stock worth $1,950,000 after acquiring an additional 22,087 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $37,689,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

TEVA has been the subject of several recent analyst reports. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Bank of America dropped their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Trading Up 2.7 %

Shares of NYSE TEVA traded up $0.43 on Friday, reaching $16.05. 4,412,871 shares of the company traded hands, compared to its average volume of 9,932,438. The company has a 50 day moving average of $15.11 and a 200 day moving average of $17.51. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market capitalization of $18.19 billion, a PE ratio of -11.08, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.